Where Sanara MedTech Stands With Analysts

4 analysts have expressed a variety of opinions on Sanara MedTech SMTI over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.75, a high estimate of $51.00, and a low estimate of $44.00. This current average has increased by 0.53% from the previous average price target of $47.50.

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light on the perception of Sanara MedTech by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sanara MedTech. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sanara MedTech compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Sanara MedTech's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into Sanara MedTech's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Sanara MedTech analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Sanara MedTech

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

Financial Milestones: Sanara MedTech's Journey

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Positive Revenue Trend: Examining Sanara MedTech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 35.24% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Sanara MedTech's net margin excels beyond industry benchmarks, reaching -13.19%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Sanara MedTech's ROE stands out, surpassing industry averages. With an impressive ROE of -7.01%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Sanara MedTech's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.53% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Sanara MedTech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.8.

Analyst Ratings: Simplified

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.